// App-Quantinova.ai

4069 : Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.

Researchers

Presenter

  • Ghassan K. Abou-Alfa

Principal Investigators

  • Milind M. Javle

  • Robin Kate Kelley

  • Sam Joseph Lubner

  • Jorge Adeva

  • James M. Cleary

  • Daniel V.T. Catenacci

  • Mitesh J. Borad

  • John A. Bridgewater

  • William Proctor Harris

  • Adrian Gerard Murphy

  • Do-Youn Oh

  • Jonathan R. Whisenant

  • Christina X. Chamberlain

  • Liewen Jiang

  • Camelia Gliser

  • Shuchi Sumant Pandya

  • Juan W. Valle

  • Andrew X. Zhu

Medical Centers

  • Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY

  • Hospital Universitario del Mar, Barcelona, Spain

  • 1.MD Anderson Cancer Center, Houston, TX

  • University of California, San Francisco, San Francisco, CA

  • University of Wisconsin Comprehensive Cancer Center, Madison, WI

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Dana-Farber Cancer Institute, Boston, MA

  • The University of Chicago Medical Center, Chicago, IL

  • Mayo Clinic, Scottsdale, AZ

  • Bart's Cancer Institute, London, United Kingdom

  • University of Washington, Seattle, WA

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of (South), Korea

  • Utah Cancer Specialists, Murray, UT

  • ARIAD Pharmaceuticals, Inc., Cambridge, MA

  • University of Manchester, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

Locations

  • United States

  • Spain

  • United Kingdom

Companies

  • Agios Pharmaceutical

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

Biomarkers

  • Isocitrate dehydrogenase 1

Drug/Treatment

  • AG120

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cross Over

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02989857

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved